[Afobasol efficacy in a model of vagotonic atrial fibrillation].
The new anxiolytic agent afobasol (Russia) was introduced into clinical practice by V. V. Zakusov Research Institute of Pharmacology. When administered to cats with vagotonic atrial fibrillation afobasol (7.5 mg/kg v/v) exhibited anti-arrhythmic activity at least as high as that of class 1 and III anti-arrhythmic agents (etacisin and cardiocyclide respectively) (Vaughan Williams classification). However, duration of its action was much smaller. These experimental findings were confirmed in clinical studies involving patients with severe psychosomatic pathology associated with paroxysmal flutter. It is supposed that afobasol activates cytosolic sigma-1 receptors in cardiomyocytes and may be used to manage psychoasthenic conditions accompanied by cardioneuroses and/or cardiophobias with disturbed rhythmic activity of the heart.
Stoliaruk
V N
VN
Vititnova
M B
MB
Tsorin
I B
IB
Kryzhanovskiĭ
S A
SA
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D001562:Benzimidazoles / Q000627:therapeutic use*; D002415:Cats; D004558:Electric Stimulation; D006801:Humans; D008297:Male; D009025:Morpholines / Q000627:therapeutic use*; D014630:Vagus Nerve / Q000503:physiopathology*
C410924:2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole; D000889:Anti-Arrhythmia Agents; D001562:Benzimidazoles; D009025:Morpholines